Editorial: New Concepts in Revascularization Strategies and Antithrombotic Therapies in Patients With Non-ST Elevated Acute Coronary Syndromes (NSTE-ACS)

Marco Mojoli^1*Krishnaraj Rathod²Marco Zuin³

• ¹Santa Maria degli Angeli Hospital, Cardiology Dpt., Azienda Sanitaria Friuli Occidentale (ASFO), Italy, Pordenone, Italy
• ²Barts Heart Centre, St. Bartholomew’s Hospital, and William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
• ³Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, Ferrara 44100, Italy

This Research Topic, "New Concepts in Revascularization Strategies and Antithrombotic Therapies in Patients With Non-ST Elevated Acute Coronary Syndromes (NSTE-ACS)," brings together several timely contributions that collectively advance the understanding of coronary revascularization decision-making, functional assessment, and precision antithrombotic care in this high-risk population.A central theme emerging from this collection is the continuous refinement of revascularization strategies in patients with NSTE-ACS. In their comprehensive review, Zuccarelli et al. (3) examined contemporary evidence comparing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in non-ST-elevation myocardial infarction (NSTEMI). Their analysis emphasizes that the choice between PCI and CABG must remain individualized, guided by anatomical complexity, comorbid burden, and procedural feasibility. Importantly, the authors highlight the key role of the multidisciplinary Heart Team in tailoring revascularization to patient-specific anatomy and profile. While PCI remains less invasive and enables faster revascularization, CABG continues to offer superior long-term freedom from myocardial infarction and repeat revascularization, particularly in patients with complex multivessel or left main disease.Further contributing to patient stratification, Sun et al. ( 4) introduced the SAVE risk score, a novel and promising tool for early identification of NSTE-ACS patients with a totally occluded infarct-related artery (IRA-TOCA). Their retrospective analysis revealed that these patients represent a distinct high-risk subgroup characterized by greater post-procedural troponin release and adverse outcomes [Ref]. The SAVE score outperformed the conventional GRACE score in identifying such cases, suggesting potential utility for early triage and prioritization of an invasive procedure. This study exemplifies the growing movement toward precision-based risk stratification to guide revascularization timing and resource allocation in NSTE-ACS care.Beyond revascularization, optimization of antithrombotic therapy represents another cornerstone of managment. Li et al. ( 5) conducted a systematic review and meta-analysis comparing ticagrelor versus clopidogrel-based dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome complicated by chronic kidney disease (CKD). Their results suggest that ticagrelor-based regimens significantly reduced the risk of major adverse cardiovascular events and stroke without a significant increase in major bleeding. Moreover, shortened DAPT duration did not confer any additional benefit. These findings reinforce current trends toward individualized DAPT tailoring, balancing ischemic and bleeding risks, especially in high-risk subgroups such as those with CKD, in whom both thrombotic and hemorrhagic risks are heightened.In a complement to these clinical perspectives, Yan et al. (6) explored innovative strategies to enhance microvascular perfusion in the setting of myocardial ischemia and reperfusion. Although primarily focused on STEMI, their discussion of intracoronary thrombolysis combined with thrombus aspiration holds conceptual relevance for patients undergoing PCI in the presence of a thrombotic lesion. Persistent microvascular obstruction (MVO) remains a major determinant of suboptimal reperfusion and adverse ventricular remodeling even after successful epicardial revascularization. By revisiting the potential role of localized thrombolytic therapy, this review revives interest in adjunctive techniques that may inform future interventional protocols.Finally, Vassilev et al. (7) presented a practical advance in the field of coronary functional assessment. Their brief report proposed an arrhythmia prevention protocol combining intravenous lidocaine pretreatment with intracoronary papaverine administration during invasive physiological testing. The study evidenced that lidocaine substantially mitigates the incidence of papaverine-induced ventricular arrhythmias while maintaining reliable hyperemia for fractional flow reserve (FFR), coronary flow reserve (CFR), and index of microcirculatory resistance (IMR) measurements. This innovation enhances procedural safety and may encourage broader clinical adoption of invasive physiological assessment in both chronic and acute coronary syndromes.Taken together, the contributions within this Research Topic exemplify the multidimensional evolution of NSTE-ACS management. The integration of refined risk stratification (SAVE score), individualized revascularization planning (Heart Team-guided PCI vs. CABG), tailored antithrombotic therapy (ticagrelor in CKD), and precision physiological assessment (lidocainepapaverine protocol) reflects the convergence of clinical evidence, technology, and care. Collectively, these studies reinforce a paradigm shift from "one-size-fits-all" strategies toward personalized, data-driven decision-making that harmonized ischemic protection, bleeding safety and procedural efficacy. The Editors hope that this Research Topic will inspire further research into the interplay between coronary pathophysiology, procedural strategy, and systemic therapy, ultimately improving the outcomes of patients with NSTE-ACS.